uniQure N.V. Files 8-K Report
Ticker: QURE · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1590560
| Field | Detail |
|---|---|
| Company | Uniqure N.V. (QURE) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financial-statements
TL;DR
uniQure filed its 8-K with financial statements and exhibits on Dec 10.
AI Summary
On December 10, 2024, uniQure N.V. filed an 8-K report to disclose financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the standard reporting requirements.
Why It Matters
This filing indicates uniQure N.V. is meeting its regulatory reporting obligations by submitting financial statements and exhibits.
Risk Assessment
Risk Level: low — This is a routine regulatory filing with no new material information or significant financial events disclosed.
Key Players & Entities
- uniQure N.V. (company) — Registrant
- December 10, 2024 (date) — Date of earliest event reported
FAQ
What is the purpose of this 8-K filing by uniQure N.V.?
The purpose of this 8-K filing is to report financial statements and exhibits as of December 10, 2024.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is December 10, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands.
What is uniQure N.V.'s telephone number?
uniQure N.V.'s telephone number is +31 - 20-566-7394.
What is the Standard Industrial Classification code for uniQure N.V.?
The Standard Industrial Classification code for uniQure N.V. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2024-12-10 07:22:53
Filing Documents
- qure-20241210x8k.htm (8-K) — 35KB
- qure-20241210xex99d1.htm (EX-99.1) — 23KB
- qure-20241210xex99d1001.jpg (GRAPHIC) — 6KB
- 0001558370-24-016106.txt ( ) — 188KB
- qure-20241210.xsd (EX-101.SCH) — 3KB
- qure-20241210_lab.xml (EX-101.LAB) — 15KB
- qure-20241210_pre.xml (EX-101.PRE) — 10KB
- qure-20241210x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 10, 2024, uniQure N.V. (the " Company ") issued a press release announcing that it had reached agreement with the U.S. Food and Drug Administration on key elements of the Company's plan to submit a Biologics License Application via the Accelerated Approval pathway for AMT-130. The Company also announced that it will host an investor call and webcast beginning at 8:30 a.m. Eastern Time on the same date, during which the Company will discuss these updates. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The virtual event can be accessed via the Events and Presentations section of the Company's website at https://www.uniqure.com/investors-media/events-presentations, and will be available for replay for 90 days following the event. The Company's website and any information contained on the website are not incorporated into this Current Report on Form 8-K. The information provided in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of such section, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of uniQure N.V. dated December 10, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. UNIQURE N.V. Date: December 10, 2024 By: /s/ Jeannette Potts JEANNETTE POTTS Chief Legal and Compliance Officer